Long repeat sequences in the C9ORF72 gene have cropped up in cases of multiple system atrophy (MSA) and depressive pseudodementia, according to two new case studies. The findings, published in JAMA ...
Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...
STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Promising new research shows Alterity’s novel brain imaging tool could play a key role in diagnosing and tracking Multiple System Atrophy. Quality peer-reviewed publication highlights use of ...
The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with ...
Hosted on MSN
Study backs Alterity’s innovative tool in diagnosing and monitoring MSA disease progression
Quality peer-reviewed publication highlights use of Alterity’s MSA Atrophy Index developed to diagnose and track MSA disease progression Tool helps pinpoint changes in brain over time, making it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback